🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06039917
Recruiting Not applicable

Effect of the Automatic Surveillance System on Surveillance Rate of Patients with Gastric Premalignant Lesions

NCT06039917 · tracked via the Priya Life Science China tracker
Sponsor
Renmin Hospital of Wuhan University
Phase
Not applicable
Started
2023-09-10
Last updated
2024-11-04

Condition(s) studied

Artificial IntelligenceSurveillance

Investigational drug(s) / intervention(s)

AI based automatic surveillance (AS) system (ENDOANGEL-AS)Manually remind the patients

AI based automatic surveillance (AS) system (ENDOANGEL-AS): An automatic surveillance (AS) system accurately identify patients with gastric premalignant lesions, assign surveillance intervals for different risks of patients and proactively follow up with patients at certain times.

Manually remind the patients: Medical staff remind patients to review manually.

Study summary

In this study, we proposed a prospective study about the effect of the automatic surveillance system on surveillance rate of patients with gastric premalignant lesions. The enrolled patients were divided into group A with intelligent surveillance system, group B with manual reminder, and group C with natural state. The surveillance among the three groups will be compared.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Male or female aged 18 years or older who undergo upper endoscopy. Exclusion Criteria: * 1)No contact information or invalid contact information. * 2\) The surveillance interval cannot be determined according to the surveillance guidelines, including no upper gastrointestinal pathology, therapeutic endoscopy or with history of previous gastrectomy, esophagectomy, or ESD, no dysplasia degrees, no biopsy sites, non-epithelial lesions, duodenal lesions, ulcer and so on. * 3\) Needless for surveillance or others. * 4\) High-grade intraepithelial neoplasia or cancer of the esophagus or stomach. * 5\) Low-grade intraepithelial neoplasia of the esophagus and Barrett's esophagus. * 6\) High-risk diseases or other special conditions for which the patient is deemed unsuitable for clinical trials by the investigator.

Primary outcome measure(s)

Trial sites (4)

FacilityCityRegionStatus
Jinjiang Municipal Hospital, Shanghai Sixth People's Hospital Fujian Campus Quanzhou Fujian Not Yet Recruiting
The Eighth Hospital of Wuhan Wuhan Hubei Not Yet Recruiting
Renmin Hospital of Wuhan University Wuhan Hubei Recruiting
Shanghai Pudong Hospital Shanghai Shanghai Municipality Recruiting

More Renmin Hospital of Wuhan University trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06039917 on ClinicalTrials.gov ↗ ← All trials in China